Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-03
2009-11-17
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
07618981
ABSTRACT:
Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders.
REFERENCES:
patent: 3978071 (1976-08-01), Nakanishi et al.
patent: 4431851 (1984-02-01), Moinet et al.
patent: 4579866 (1986-04-01), Stevenson et al.
patent: 5158959 (1992-10-01), Geiger et al.
patent: 5401766 (1995-03-01), Geiger et al.
patent: 6204282 (2001-03-01), Neustadt et al.
patent: 6214877 (2001-04-01), Butera et al.
patent: 6545004 (2003-04-01), Finer et al.
patent: 6908929 (2005-06-01), Breitenbucher et al.
patent: 7504413 (2009-03-01), Qian et al.
patent: 2002/0183249 (2002-12-01), Taylor et al.
patent: 2005/0075356 (2005-04-01), DiFrancesco et al.
patent: 2008/0255182 (2008-10-01), Qian et al.
patent: 2 905 883 (1980-08-01), None
patent: 8.005 (1970-07-01), None
patent: 52113992 (1977-09-01), None
patent: 61-000054 (1986-01-01), None
patent: WO 97/08133 (1997-03-01), None
patent: WO 98/56756 (1998-12-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/61410 (1999-12-01), None
patent: WO 00/39077 (2000-07-01), None
patent: WO 01/44154 (2001-06-01), None
patent: WO 01/68619 (2001-09-01), None
patent: WO 02/18327 (2002-03-01), None
patent: WO 02/096864 (2002-12-01), None
patent: WO 2004/004652 (2004-01-01), None
patent: WO 2004/056784 (2004-07-01), None
patent: WO 2004/071448 (2004-08-01), None
patent: WO 2004/087720 (2004-10-01), None
Patterson et. al. The Ring Index, Reinhold: New York, 1940, p. 122.
Sunder-Plassman et. al, “Synthesis and biological evaluation of new tetrahydro-b-carbolines as inhibitors of the mitotic kinesin Eg5” Bioorganic & Medicinal Chemistry 2005, 13, 6094-6111.
Tarby et. al. “Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series” . Bioorganic & Medicinal Chemistry Letters 2006, 16, 2095-2100.
Cox et. al. “Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diary1-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP” Bioorganic & Medicinal Chemistry Letters 2005 15, 2041-2045.
Wolff, M.E. Burger's Medicinal Chemistry 4th Ed. Part I, Wiley: New York, 1979, 336-337.
Dorwald, F.A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Hyun, et al. “Improved Chiral Stationary Phase Derived from (S)-Naproxen for the Liquid Chromatographic Resolution of Enantiomers,” J. Chromatogr. A, 732: 209-214 (1996).
Jackson, et al. Journal of Organic Chemistry, 1998, 63, 7875-7884.
Kim et al. “Synthesis and SAR of pyrrolotriazine-4-one based Eg5 Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2006, 16, 3937-3942.
Kosolapoff, G.M. Journal of the American Chemical Society, 1953, 75, 3596-3597.
“Lithium Aluminium Hydride” Paquette, L. in Encyclopedia of Reagents for Organic Synthesis Online Posting Date: Oct. 15, 2004 John Wiley & Sons, Ltd. “http://www.mrw.interscience.wiley.com/eros/articles/rl036/frame.html”.
Office Action dated May 29, 2007 for U.S. Appl. No. 11/271,147, filed Nov. 9, 2005.
Notice of Allowance dated Oct. 29, 2007 for U.S. Appl. No. 11/271,147, filed Nov. 9, 2005.
International Search Report and Written Opinion, mailed May 4, 2006, for International Application No. PCT/US05/15666, filed May 6, 2005.
International Search Report, dated Sept. 7, 2007, for International Application No. PCT/US2006/042801, filed Nov. 2, 2005.
International Search Report and Written Opinion, mailed Sep. 24, 2007, for International Application No. PCT/US06/43514, filed Nov. 8, 2006.
Supplemental Partial European Search Report completed Nov. 27, 2007 for European application No. EP 05 76 2665.
Office Action dated May 20, 2008 for U.S. Appl. No. 11/598,250, filed Nov. 8,2006.
Notice of Allowance dated Apr. 23, 2008, for U.S. Appl. No. 11/217,147.
Office Action dated Jun. 23, 2008 for U.S. Appl. No. 11/124,608.
Notice of Allowance dated Oct. 10, 2008, for U.S. Appl. No. 11/271,147.
Office Action dated Nov. 20, 2008 for U.S. Appl. No. 11/598,250, filed Nov. 8, 2006.
Office Action dated Dec. 16, 2008 for U.S. Appl. No. 11/124,608.
Advisory Action dated Apr. 3, 2009 for U.S. Appl. No. 11/124,608.
Notice of Allowance dated Apr. 10, 2009 for U.S. Appl. No. 11/598,250.
Arndts et al., “Evaluation of clonidine plasma levels in man using a highly sensitive radioimmunoassay,”Methods Clin. Pharmacol., Proc. Int Symp., Meeting Date 1979, 279-86 (1980).
Bebernitz et al., “Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase,”Journal of Medicinal Chemistry, 43(11), 2248-57 (2000).
Breysse et al., “Potential psychotropic agents. V. Synthesis and pharmacological study of 4-alkoxy-3,5-dihalobenzoyl hydrazines inhibiting monoamine oxidase,”Chimica Therapeutica, 4(3), 157-66 (1969).
Gombar et al., “Quantitative structure-activity relationship studies: β-adrenergic blocking activity of 1-(2,4-disubstituted phenoxy)-3-aminopropan-2-ols,”European Journal of Medicinal Chemistry, 25(8), 689-95 (1990).
Iwamura et al., “Prophylactic effect of JTE-607 on LPS-induced acute lung injury in rats with CINC-1 inhibition,”Inflammation Research, 51(3), 160-66 (2002).
Kakutani et al, “JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice,”Inflammation Research, 48(8), 461-468 (1999).
Smith, “β-Adrenergic blocking agents. 13. (3-Amino-2- hydroxypropoxy)benzamides,” Journal of Medicinal Chemistry, 19(9), 1119-23 (1976).
Qian et al., U.S. Appl. No. 11/124,608, filed May 6, 2005, entitled “Certain Chemical Entities, Compositions, and Methods,” 320 pages.
Chemical Abstracts Registry No. 22476-72-8, 2000.
Chemical Abstracts Registry No. 315675-64-0, 2000.
Chemical Abstracts Registry No. 356550-38-4, 2000.
Chemical Abstracts Registry No. 506428-81-5, 2000.
Adams Nicholas D.
Ashcraft Luke W.
Bergnes Gustave
Dhanak Dashyant
Duffy Kevin
Cytokinetics Inc.
Desai Rita J
Finnegan Henderson Farabow Garrett & Dunner LLP
O'Dell David K
SmithKline Beecham Corporation
LandOfFree
Imidazopyridinyl-benzamide anti-cancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyridinyl-benzamide anti-cancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyridinyl-benzamide anti-cancer agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107015